NCT02219737View on ClinicalTrials.gov

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2014

Primary Completion Date

May 11, 2017

Study Completion Date

May 11, 2017

Conditions

CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Carboplatin

Given IVPB

DRUG

Etoposide

Given IVPB

DRUG

Ibrutinib

Given PO

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02219737 - Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter